Results 11 to 20 of about 3,811,568 (245)

Novel Strategies for Treating Castration-Resistant Prostate Cancer

Biomedicines, 2021
The development of castration resistance is an inevitable pathway for the vast majority of patients with advanced prostate cancer. Recently, there have been significant breakthroughs in the understanding and management options of castration-resistant ...
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh   +3 more
doaj   +2 more sources

Epiregulin expression and secretion is increased in castration-resistant prostate cancer [PDF]

Frontiers in Oncology, 2023
IntroductionIn prostate cancer, long-term treatment directed against androgens often leads to the development of metastatic castration-resistant prostate cancer, which is more aggressive and not curatively treatable.
Marc Wiesehöfer, Benedikt Bernhard Gereon Raczinski, Caroline Wiesehöfer, Jaroslaw Thomas Dankert, Elena Dilara Czyrnik, Martin Spahn, Martin Spahn, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Gunther Wennemuth   +11 more
doaj   +3 more sources

Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2. [PDF]

Mol Oncol
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Chatterjee J, Marin A, Yalala S, Itkonen HM.   +3 more
europepmc   +2 more sources

Control of gene expression in prostate epithelial cell differentiation hierarchy [PDF]

, 2012
The aim of present investigation is to elucidate the complex stem cell (SC) dynamics within prostate cancer, which can be exploited to design novel diagnostic and therapeutic strategies for the management of prostate cancer.
Rane, Jayant
core   +6 more sources

Diethylstilbestrol in castration‐resistant prostate cancer [PDF]

BJU International, 2012
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Diethylstilbestrol (DES) was the first hormone treatment used for prostate cancer and has also ...
Wilkins, A, Shahidi, M, Parker, C, Gunapala, R, Thomas, K, Huddart, R, Horwich, A, Dearnaley, D   +7 more
openaire   +6 more sources

The biology of castration-resistant prostate cancer [PDF]

Current Problems in Cancer, 2015
Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer death in men in the United States. Although there are recently approved therapeutic options for men with advanced and metastatic disease, the unfortunate reality is that advanced prostate cancer is inevitably fatal. Hormonal androgen deprivation therapy
Fei, Lian, Nitya V, Sharma, Josue D, Moran, Carlos S, Moreno   +3 more
openaire   +2 more sources

Mitoribosome sensitivity to HSP70 inhibition uncovers metabolic liabilities of castration-resistant prostate cancer. [PDF]

, 2023
The androgen receptor is a key regulator of prostate cancer and the principal target of current prostate cancer therapies collectively termed androgen deprivation therapies.
Shrimp, Jonathan H, Maisiak, M, Gestwicki, JE, Nisbet, Ian, Jonathan H Shrimp, Ralph, SJ, Jason E Gestwicki, Murali Krishna Cherukuri, Cherukuri, Murali Krishna, Cherukuri, MK, Shrimp, JH, Marisa Maisiak, Neckers, Leonard M, Maisiak, Marisa, Genesis M Rivera-Marquez, Oleta T Johnson, Ishida, R, Johnson, OT, Echtenkamp, FJ, Rivera-Marquez, Genesis M, Ryo Ishida, Leonard M Neckers, Ishida, Ryo, Sinha, Arnav, Rivera-Marquez, GM, Ralph, Stephen John, Gestwicki, Jason E, Echtenkamp, Frank J, Johnson, Oleta T, Frank J Echtenkamp, Sinha, A, Stephen John Ralph, Ian Nisbet, Nisbet, I, Arnav Sinha, Neckers, LM   +35 more
core   +1 more source

Castrate-resistant prostate cancer [PDF]

Current Opinion in Urology, 2013
Prior to 2010, docetaxel was the only treatment shown to prolong survival in metastatic castrate-resistant prostate cancer (CRPC). In the past 3 years, several therapeutic agents have demonstrated survival improvements for CRPC after the receipt of prior docetaxel, leading to multiple approvals by the US Food and Drug Administration.The development of ...
Song, Zhao, Evan Y, Yu
openaire   +2 more sources

Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer

Pharmaceutics, 2021
Heat shock protein 27 (Hsp27) has an established role in tumor progression and chemo-resistance of castration-resistant prostate cancer (CRPC). Hsp27 protects eukaryotic translation initiation factor 4E (eIF4E) from degradation, thereby maintaining ...
Hajer Ziouziou, Clément Paris, Sébastien Benizri, Thi Khanh Le, Claudia Andrieu, Dang Tan Nguyen, Ananda Appavoo, David Taïeb, Frédéric Brunel, Ridha Oueslati, Olivier Siri, Michel Camplo, Philippe Barthélémy, Palma Rocchi   +13 more
doaj   +1 more source

Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy

Frontiers in Bioengineering and Biotechnology, 2022
Introduction: Erythropoietin producing hepatocyte receptor A2 (EphA2) is widely presented in the tumor cells, closely related to tumor cell migration, not cell apoptosis and proliferation.
Chao-Gang Wei, Rui Zhang, Lan-Yi Wei, Peng Pan, He Zu, Ya-Zhen Liu, Yong Wang, Jun-Kang Shen   +7 more
doaj   +1 more source